A Phase I-II Study on Stereotactic Body Radiotherapy in 3 Fractions for Low/Int Risk Prostate Cancer

NCT ID: NCT02623647

Last Updated: 2021-03-09

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: NA
• Total Enrollment: 150 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2015-11-30
• Study Completion Date: 2022-01-31

Brief Summary

The present is a phase I-II study testing the safety and the efficacy of extremely hypofractionated radiotherapy for early stage prostate cancer. The study is designed to assess GU toxicity while controlling tumor control, in terms of survival free from biochemical failure. 40 Gy in fxs will be delivered to patients with low and favourable intermediate risk prostate tumors.

Detailed Description

In the last two decades several studies have shown an exclusive sensitivity of prostate cancer cells to low doses per fraction. It has been postulated that the effect of fractionation is protective against tumor cells rather than both acute and late responding normal tissues, and this in turn tends to decrease the therapeutic index. The schedule tested here is considered biologically equivalent to deliver to the tumor, at 2 Gy per fraction, a total dose of approximately 170 Gy or more than twice of the reference schedule (76-80 Gy). On the contrary, the schedule is considered to deliver a dose of 78 Gy and 130 Gy on acute (i.e mucosa)(a/b =10 Gy) and late (a/b =3 Gy)(i.e. rectum, bladder) responding tissues.

Main selection criteria: Patients (>18 yrs/old) with low risk (primary tumor stage according to AJCC 2010: T1-2a and Gleason Score-GLS: 3+3 and serum Prostate Specific Antigen-PSA: PSA<10 ng/ml) and among those with intermediate risk features (clinical stage T2b-c or GLS 7 or PSA of 10-20 ng/ml) those with favorable ones (a single factor for intermediate risk and GLS 3 + 4 and <50% of biopsy cores containing cancer) will be selected.

Work up & pretreatment procedures: A diagnostic biopsy with at least 10 cores is needed. Patients will undergo in local anesthesia the placement both 4 fiducials (or 'gold seeds') and a gel spacer between the prostate and the rectum at least one week before the simulation. Both the seeks and the gel spacer are implanted throughout the perineum. The gel will be inserted between the posterior aspect the prostate and the anterior rectal wall to obtain a space of at least 5 mm in thickness between the two structures.

Treatment outline: Patients will be treated with EBRT, Volumetric Arc Radiotherapy on the prostate only to the total dose of 40 Gy in 3 fractions, every other day (dose per fraction=13.3 Gy). While neoadjuvant androgen deprivation is allowed for up to 3 months, no concomitant/adjuvant (to eHYPO) androgen deprivation is allowed.

Simulation & Planning: Patients will undergo both CT and MR of the pelvis for planning purposes, in the supine position.

The clinical target volume (CTV) is represented by the prostate as identified on MR images (coregistered with the CT). During both CT and MR scans the patient will be catheterized (to identify the urethra) and the bladder filled with saline, 250 cc. The prostate (target) will be contoured on the MR and expanded by 4 mm isotropically for planning purposes to obtain the Planning Target Volume (PTV). The rectal wall, bladder wall, bladder trigone, prostate urethra, intestinal cavity, rectal spacer, penile bulb, femoral heads will be contoured as well. The treatment will be planned with Volumetric Arc Modulated Therapy. Before each treatment fraction, the correct set up of the prostate will be done comparing the spatial position of the 4 fiducials on the planning CT and the CBCT. Patients will be seen at each treatment, one month after treatment completion and every three months afterwards for up to 2 yrs. Serum PSA will be obtained at each follow up after treatment. Regarding disease control, outcome will computed in terms of biochemical control free survival, or survival with biochemical control. This will defined according to the 'Phoenix' definition of 'nadir plus 2 ng/ml'. Toxicity will be recorded with CTCAE v4.0 at each examination. Before treatment and at both 12 and 24 month follow ups patients will report QoL (EORTC and FACT-P), IPSS, urinary continence (ICIQ-SF) and sexual activity (IIEFS). At 12 and 24 months they will be asked to report satisfaction with treatment (FACIT-I).

Conditions

Prostate Cancer

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

A single-arm, nonrandomized

stereotactic body radiotherapy SBRT, 40 Gy for 3 fractions

Group Type: OTHER

stereotactic body radiotherapy SBRT

Intervention Type: RADIATION

40 Gy in 3 fractions to the prostate gland delivered with stereotactic body radiotherapy

Interventions

stereotactic body radiotherapy SBRT

40 Gy in 3 fractions to the prostate gland delivered with stereotactic body radiotherapy

Intervention Type: RADIATION

Eligibility Criteria

Inclusion Criteria

• age (>18 yrs/old)
• low risk prostate cancer defined as primary tumor stage according to AJCC 2010: T1-2a and Gleason Score-GLS: 3+3 and serum Prostate Specific Antigen-PSA: PSA<10 ng/ml); or among intermediate risk prostate cancer defined as clinical stage T2b-c or GLS 7 or PSA of 10-20 ng/ml, only patients with favourable characteristics: a single factor for intermediate risk AND GLS 3 + 4 AND <50% of biopsy cores containing cancer (12 cores as a minimum).

Exclusion Criteria

• prior radiotherapy
• concomitant androgen deprivation
• pt failure to consent

• Minimum Eligible Age: 18 Years
• Eligible Sex: MALE
• Accepts Healthy Volunteers: No

Sponsors

San Giovanni Addolorata Hospital

OTHER

Sponsor Role: collaborator

Azienda Sanitaria-Universitaria Integrata di Udine

OTHER

Sponsor Role: collaborator

Regina Elena Cancer Institute

OTHER

Sponsor Role: lead

Responsible Party

Giuseppe Sanguineti

Chairman, Dept of Radiation Oncology

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Giuseppe Sanguineti, MD

Role: PRINCIPAL_INVESTIGATOR

Regina Elena National Cancer Institute, Rome IT

Locations

Regina Elena National Cancer Institute

Rome, , Italy

Site Status: RECRUITING

Countries

Italy

Central Contacts

Giuseppe Sanguineti, MD

Role: CONTACT

giuseppe.sanguineti@ifo.gov.it

+390652663010

Other Identifiers

eHYPO

Identifier Type: -

Identifier Source: org_study_id